Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) Net Income towards Common Stockholders (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Net Income towards Common Stockholders data on record, last reported at $414.1 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 728.53% year-over-year to $414.1 million; the TTM value through Dec 2025 reached $1.2 billion, up 426.61%, while the annual FY2025 figure was $1.2 billion, 442.41% up from the prior year.
  • Net Income towards Common Stockholders reached $414.1 million in Q4 2025 per PTCT's latest filing, up from -$23.1 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $866.6 million in Q1 2025 and bottomed at -$198.9 million in Q2 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$44.3 million, with a median of -$122.5 million recorded in 2021.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 123.47% in 2021, then soared 1046.28% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$143.3 million in 2021, then decreased by 19.28% to -$170.9 million in 2022, then rose by 8.83% to -$155.8 million in 2023, then soared by 57.71% to -$65.9 million in 2024, then surged by 728.53% to $414.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were $414.1 million in Q4 2025, -$23.1 million in Q3 2025, and -$71.1 million in Q2 2025.